首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

导出 LinkOut

翻译打印收藏纠错

第一作者： Anna,Guidetti

第一单位： Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy.

作者： Anna,Guidetti ^[1] ; Carmelo,Carlo-Stella ^[2] ; Silvia L,Locatelli ^[3] ; Walter,Malorni ^[4] ; Roberta,Mortarini ^[5] ; Simonetta,Viviani ^[6] ; Domenico,Russo ^[7] ; Alfonso,Marchianò ^[8] ; Roberto,Sorasio ^[9] ; Anna,Dodero ^[10] ; Lucia,Farina ^[10] ; Laura,Giordano ^[11] ; Massimo,Di Nicola ^[6] ; Andrea,Anichini ^[5] ; Paolo,Corradini ^[12] ; Alessandro M,Gianni ^[1]

作者单位： Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy. ^[1] Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy. Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy. carmelo.carlostella@unimi.it. ^[2] Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy. Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy. ^[3] Istituto Superiore di Sanità, Roma, Italy. San Raffaele Institute, Sulmona, Italy. ^[4] Human Tumors Immunobiology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. ^[5] Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. ^[6] Hematology and BMT Unit, University of Brescia, Brescia, Italy. ^[7] Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. ^[8] Division of Hematology, S. Croce & Carle Hospital, Cuneo, Italy. ^[9] Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. ^[10] Biostatistic Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy. ^[11] Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. Hematology, University of Milano, Milano, Italy. ^[12]